Version history
This page records the controlled revision history of these instructions for use (IFU). In accordance with Section 23.4(y) of Annex I (General Safety and Performance Requirements) of Regulation (EU) 2017/745 (the MDR), it provides the date of issue of this IFU and, for any subsequent revision, the date of issue and the identifier of that revision.
Each entry corresponds to a single approved change to the IFU. Consistent with our Quality Management System (procedure GP-001), every revision is uniquely and tamper-evidently identified and retained within the manufacturer's controlled document system. The identifier of the latest revision is the Version shown in the most recent row of the table below, together with its date of issue. The Date column records the approval date, that is, the date on which the revision was approved under this document's defined approval chain. The Version column gives a sequential, human-readable label.
Because this IFU is a digital document, every change made anywhere in it is accompanied by a new entry in the table below, so this page always reflects the latest released version.
| Version | Date | Summary of changes |
|---|---|---|
| 1 | 2026-06-23 | Initial release. |
| 2 | 2026-06-25 | Removed the draft qualifier from the EU MDR CE marking notice on the Table of contents. |
| 3 | 2026-09-14 | Completed the Portuguese translation of the device label and its accompanying safety information. |
| 4 | 2026-10-01 | Added APOTECH CONSULTING LIMITED as the UK Responsible Person on the device label. The change itself was made on 2026-08-27 and was not entered in this table at the time; this entry records it retrospectively. |
| 5 | 2026-10-01 | Removed the draft qualifier from the EU MDR CE marking on the device label, following the issue of certificate MDR 792790 by BSI, notified body 2797. |
| 6 | 2026-10-05 | Aligned the colour bands of the malignancy gauge with the Low, Moderate and High thresholds stated in the table below it. |
| 7 | 2026-10-07 | Added a French translation of these instructions for use. |
| 8 | 2026-10-07 | Revised the contraindications to align them with the intended purpose: the items on skin folds, nails, hair, bleeding, tattoos, creams and scars are kept as the situations in which they limit the analysis, rather than as exclusions of structures the device is intended for; added images that do not show skin, non-pigmented lesions photographed through a dermatoscope, images the device reports as having insufficient quality, use of the result as the only basis for a decision, and conditions that are not visible or not visibly distinguishable; removed the eye-distance item. Revised the mandatory integration requirements of the Installation Manual: image quality, entropy and, where produced, the severity assessment join the mandatory report elements; the selection of the problem type, the capture instructions, an image cropper and the image quality check are mandatory for the user who captures the images, with a new Image cropper section describing how the cropper works; the binary safety indicators become recommended, with the referral recommendation as the referral output; and the thresholds are stated as suggested ranges that the organisation sets for its use case. Removed sensitivity and specificity from the list of report metadata. |
| 9 | 2026-10-26 | Corrected the window of the high-priority referral indicator in the endpoint specification of the Installation Manual from 7-15 days to 7-14 days, consistent with the two weeks stated for the same indicator in the same manual. |
| 10 | 2026-10-29 | Added a fourth capture instruction for other conditions to the Installation Manual, with its illustration: do not use a dermatoscope, take the photo with the mobile phone's camera. |